Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged chemotherapy
When did Mylan agree to launch its Herceptin biosimilar?

Mylan’s biosimilar for Herceptin® has FDA approval since December 2017.  Several months earlier, in March 2017, Mylan reached a global settlement with Roche and Genentech regarding their patents covering the drug.  The terms of the settlement have not been made public, which raises the question – when did Mylan agree to launch? 

Read More
Markman AdvisorsMylan, Herceptin, Rituxan, FDA, Roche, Genentech, Inter Partes Review, IPR, chemotherapy, biosimilar, Humira, BPCIA, Celltrion, Teva, Amgen, Samsung, Pfizer Comment